Epidermal growth factor receptor inhibitors in cancer treatment. (Q36429442)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Epidermal growth factor receptor inhibitors in cancer treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Fortunato Ciardiello

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

221-234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json

Autocrine secretion and malignant transformation of cells.

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

The epidermal growth factor receptor as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Targeting targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Targeting epidermal growth factor receptor--are we missing the mark?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Practical management of patients with non-small-cell lung cancer treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.221

21 January 2018

Identifiers

DOI

10.1517/14796694.1.2.221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16555994%20AND%20SRC:MED&resulttype=core&format=json